Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.56 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16100146 | 1.00 | KMT2A (0.56) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL16094559 | 0.81 | FBP1 (0.39) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL574174 | 0.81 | KMT2A (0.51) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL16094560 | 0.81 | FBP1 (0.39) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL16094294 | 0.80 | KMT2A (0.38) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL16094296 | 0.80 | KMT2A (0.38) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL4712427 | 0.80 | KMT2A (0.50) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL2559554 | 0.80 | KMT2A (0.50) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL16094770 | 0.80 | MEN1 (0.45) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL4715183 | 0.80 | MEN1 (0.45) | KMT2AMEN1GABBR2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968331-B1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-07-01 | — | — | EP | claimed |
| EP-3733184-B1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3733184-A1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Icahn School of Medicine at Mount Sinai (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-2968331-B1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-07-01 | — | — | EP | disclosed |
| US-9815847-B2 | Pyrimidine compounds as kinase inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815847-B2 | Pyrimidine compounds as kinase inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160122361-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2016-05-05 | — | — | US | disclosed |
| US-20160122361-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2016-05-05 | — | — | US | disclosed |
| EP-2968331-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | Icahn School of Medicine at Mount Sinai (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151682-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151682-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122361-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | DCK, TK1, DTYMK | KMT2A 1361/4885MEN1 2972/4885GABBR2 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.